temozolomide has been researched along with Cancer of Pancreas in 53 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Orally administered temozolomide and thalidomide seems to be an active regimen for the treatment of neuroendocrine tumors." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "We evaluated outcomes of treatment with 5-fluorouracil (5-FU), doxorubicin, and streptozocin (FAS) in well-differentiated pancreatic neuroendocrine tumors (PanNETs) and its impact on subsequent therapy (everolimus or temozolomide)." | 8.12 | Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. ( Dagohoy, CG; Dasari, A; Halperin, DM; Lam, M; Rogers, JE; Yao, JC, 2022) |
| "The role of alternate sequential administration of sunitinib and capecitabine/temozolomide (CAPTEM) in metastatic pancreatic neuroendocrine tumors (PanNETs) remains unexplored." | 8.12 | Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors. ( Dong, J; Gao, H; Li, H; Liu, L; Ni, Q; Wang, W; Xu, H; Ye, L; Zhang, W, 2022) |
| "5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) has activity in pancreatic neuroendocrine tumors (pNETs), but its use is limited, partly because of toxicities." | 8.02 | Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. ( Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J, 2021) |
| "The combination chemotherapy regimen capecitabine/temozolomide (CAPTEM) is efficacious for metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs), but its role in the neoadjuvant setting has not been established." | 7.96 | Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors. ( Abdel-Misih, S; Cloyd, JM; Dillhoff, ME; Dua, M; Konda, B; Norton, JA; Pawlik, TM; Poultsides, G; Schmidt, CR; Shah, MH; Squires, MH; Visser, BC; Worth, PJ, 2020) |
| "Although chemotherapy combining 5-fluorouracil (5FU)-dacarbazine (DTIC) or temozolomide (TEM)-capecitabine (CAP) is extensively used in patients with neuroendocrine tumors (NET), they were never compared." | 7.91 | Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. ( Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T, 2019) |
| "Temozolomide (TMZ) is an alkylating agent frequently used in well-differentiated metastatic pancreatic neuroendocrine tumors (PNETs) with very variable responses." | 7.85 | Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. ( Caroli-Bosc, FX; Cauchin, E; Dumars, C; Foubert, F; Girot, P; Matysiak-Budnik, T; Mosnier, JF; Muzellec, L; Regenet, N; Senellart, H; Touchefeu, Y, 2017) |
| "Temozolomide (TEM) showed encouraging results in well-differentiated pancreatic neuroendocrine tumors (WDPNETs)." | 7.83 | MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. ( Bedossa, P; Couvelard, A; Cros, J; Gille, N; Hammel, P; Hentic, O; Lévy, P; Maire, F; Paradis, V; Rebours, V; Ruszniewski, P; Theou-Anton, N; Vernerey, D; Zappa, M, 2016) |
| "The capecitabine and temozolomide (CAPTEM) regimen is active in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs), with response rates ranging from 30 to 70%." | 7.83 | Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. ( Black, M; Brelsford, M; Cives, M; Ghayouri, M; Meeker, A; Morse, B; Rizzo, A; Strosberg, J, 2016) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 7.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 7.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "MGMT deficiency, measured by immunohistochemistry, is more common in pancreatic neuroendocrine tumors than in carcinoid tumors as is treatment response to temozolomide-based therapy." | 7.75 | O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Frauenhoffer, C; Fuchs, CS; Hooshmand, S; Hornick, JL; Kulke, MH; Meyerhardt, JA; Redston, MS; Ryan, DP; Stuart, K, 2009) |
| "The aim of the present study was to assess the effect of Endostar and temozolomide or dacarbazine plus 5-fluorouracil (5-FU) in patients with advanced pancreatic neuroendocrine tumors (pNETs)." | 5.27 | Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors. ( Bai, CM; Cheng, YJ; Gao, X; Meng, CT; Yan, XY; Ying, HY; Zhou, JF; Zhou, N, 2018) |
| "Orally administered temozolomide and thalidomide seems to be an active regimen for the treatment of neuroendocrine tumors." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "The combination of capecitabine and temozolomide (CAPTEM) is one of the treatment options for metastatic pancreatic neuroendocrine neoplasms (pNENs)." | 4.12 | Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience. ( Chun, JW; Douangprachanh, S; Han, N; Han, SS; Jang, HY; Joo, HJ; Kim, TH; Koh, YH; Lee, WJ; Park, HM; Park, SJ; Woo, SM, 2022) |
| "We evaluated outcomes of treatment with 5-fluorouracil (5-FU), doxorubicin, and streptozocin (FAS) in well-differentiated pancreatic neuroendocrine tumors (PanNETs) and its impact on subsequent therapy (everolimus or temozolomide)." | 4.12 | Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. ( Dagohoy, CG; Dasari, A; Halperin, DM; Lam, M; Rogers, JE; Yao, JC, 2022) |
| "The role of alternate sequential administration of sunitinib and capecitabine/temozolomide (CAPTEM) in metastatic pancreatic neuroendocrine tumors (PanNETs) remains unexplored." | 4.12 | Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors. ( Dong, J; Gao, H; Li, H; Liu, L; Ni, Q; Wang, W; Xu, H; Ye, L; Zhang, W, 2022) |
| "5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) has activity in pancreatic neuroendocrine tumors (pNETs), but its use is limited, partly because of toxicities." | 4.02 | Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. ( Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J, 2021) |
| "The capecitabine/temozolomide (CAPTEM) regimen has significant activity in advanced neuroendocrine tumors (NETs)." | 4.02 | Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms. ( Al-Toubah, T; Haider, M; Pelle, E; Strosberg, JR; Valone, T, 2021) |
| "The combination chemotherapy regimen capecitabine/temozolomide (CAPTEM) is efficacious for metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs), but its role in the neoadjuvant setting has not been established." | 3.96 | Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors. ( Abdel-Misih, S; Cloyd, JM; Dillhoff, ME; Dua, M; Konda, B; Norton, JA; Pawlik, TM; Poultsides, G; Schmidt, CR; Shah, MH; Squires, MH; Visser, BC; Worth, PJ, 2020) |
| "The combination of capecitabine (CAP) with temozolomide (TEM) chemotherapy in advanced pancreatic neuroendocrine tumors (PanNET) relies on limited evidence." | 3.96 | Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor. ( Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T, 2020) |
| "Although chemotherapy combining 5-fluorouracil (5FU)-dacarbazine (DTIC) or temozolomide (TEM)-capecitabine (CAP) is extensively used in patients with neuroendocrine tumors (NET), they were never compared." | 3.91 | Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. ( Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T, 2019) |
| "Temozolomide (TMZ) is an alkylating agent frequently used in well-differentiated metastatic pancreatic neuroendocrine tumors (PNETs) with very variable responses." | 3.85 | Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. ( Caroli-Bosc, FX; Cauchin, E; Dumars, C; Foubert, F; Girot, P; Matysiak-Budnik, T; Mosnier, JF; Muzellec, L; Regenet, N; Senellart, H; Touchefeu, Y, 2017) |
| "Temozolomide (TEM) showed encouraging results in well-differentiated pancreatic neuroendocrine tumors (WDPNETs)." | 3.83 | MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. ( Bedossa, P; Couvelard, A; Cros, J; Gille, N; Hammel, P; Hentic, O; Lévy, P; Maire, F; Paradis, V; Rebours, V; Ruszniewski, P; Theou-Anton, N; Vernerey, D; Zappa, M, 2016) |
| "The capecitabine and temozolomide (CAPTEM) regimen is active in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs), with response rates ranging from 30 to 70%." | 3.83 | Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. ( Black, M; Brelsford, M; Cives, M; Ghayouri, M; Meeker, A; Morse, B; Rizzo, A; Strosberg, J, 2016) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 3.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 3.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "MGMT deficiency, measured by immunohistochemistry, is more common in pancreatic neuroendocrine tumors than in carcinoid tumors as is treatment response to temozolomide-based therapy." | 3.75 | O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Frauenhoffer, C; Fuchs, CS; Hooshmand, S; Hornick, JL; Kulke, MH; Meyerhardt, JA; Redston, MS; Ryan, DP; Stuart, K, 2009) |
| "Temozolomide (SCH 52365) is an imidazotetrazine derivative which exhibits broad spectrum activity against murine tumors and is structurally related to dacarbazine (DTIC)." | 2.69 | A phase II study of temozolomide in advanced untreated pancreatic cancer. ( Feld, R; Hedley, D; Moore, MJ; Oza, A; Siu, LL, 1998) |
| "Advanced neuroendocrine tumors are incurable, and most patients will succumb to the disease." | 2.52 | Cytotoxic chemotherapy for pancreatic neuroendocrine tumors. ( Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Takahashi, H; Ueno, H, 2015) |
| "Temozolomide (TEM) has been reported to be active alone or in combination with capecitabine (CAP) in patients with neuroendocrine neoplasms (NENs)." | 1.62 | Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. ( Antonuzzo, L; Barberis, M; Campana, D; Faviana, P; Fazio, N; Fumagalli, C; Gelsomino, F; Maisonneuve, P; Marconcini, R; Messerini, L; Puliafito, I; Rossi, G; Spada, F, 2021) |
| " According with the poor Performance Status (PS = 2) and to reduce the toxicity of the treatment was chosen an intermittent dosing regimen of metronomic temozolomide (75 mg/m(2)/day-one-week-on/on-week-off)." | 1.43 | Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. ( Arcella, A; Ascierto, PA; Cicala, D; De Divitiis, C; Grimaldi, AM; Iaffaioli, RV; Romano, GM; Simeone, E; Tafuto, S; Tatangelo, F; von Arx, C, 2016) |
| "Necrolytic migratory erythema is an obligatory paraneoplastic syndrome." | 1.39 | Necrolytic migratory erythema in a patient with neuroendocrine carcinoma. ( Enk, AH; Gronau, M; Hassel, JC; Jäger, D, 2013) |
| "Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results." | 1.38 | Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ( Federspiel, B; Hansen, CP; Kjaer, A; Knigge, U; Langer, SW; Olsen, IH; Sørensen, JB, 2012) |
| "Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas." | 1.37 | First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. ( Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.89) | 18.2507 |
| 2000's | 5 (9.43) | 29.6817 |
| 2010's | 31 (58.49) | 24.3611 |
| 2020's | 16 (30.19) | 2.80 |
| Authors | Studies |
|---|---|
| Papeo, G | 1 |
| Posteri, H | 1 |
| Borghi, D | 1 |
| Busel, AA | 1 |
| Caprera, F | 1 |
| Casale, E | 1 |
| Ciomei, M | 1 |
| Cirla, A | 1 |
| Corti, E | 1 |
| D'Anello, M | 1 |
| Fasolini, M | 1 |
| Forte, B | 1 |
| Galvani, A | 1 |
| Isacchi, A | 1 |
| Khvat, A | 1 |
| Krasavin, MY | 1 |
| Lupi, R | 1 |
| Orsini, P | 1 |
| Perego, R | 1 |
| Pesenti, E | 1 |
| Pezzetta, D | 1 |
| Rainoldi, S | 1 |
| Riccardi-Sirtori, F | 1 |
| Scolaro, A | 1 |
| Sola, F | 1 |
| Zuccotto, F | 1 |
| Felder, ER | 1 |
| Donati, D | 1 |
| Montagnoli, A | 1 |
| Douangprachanh, S | 1 |
| Joo, HJ | 1 |
| Park, HM | 1 |
| Han, N | 1 |
| Jang, HY | 1 |
| Koh, YH | 1 |
| Kim, TH | 1 |
| Han, SS | 1 |
| Park, SJ | 1 |
| Lee, WJ | 1 |
| Woo, SM | 1 |
| Chun, JW | 1 |
| Navale, P | 1 |
| Chatterjee, D | 1 |
| Itani, M | 1 |
| Trikalinos, NA | 1 |
| Wu, YL | 1 |
| Raj, N | 2 |
| Reidy-Lagunes, D | 3 |
| Squires, MH | 1 |
| Worth, PJ | 1 |
| Konda, B | 1 |
| Shah, MH | 1 |
| Dillhoff, ME | 1 |
| Abdel-Misih, S | 1 |
| Norton, JA | 1 |
| Visser, BC | 1 |
| Dua, M | 1 |
| Pawlik, TM | 1 |
| Schmidt, CR | 1 |
| Poultsides, G | 1 |
| Cloyd, JM | 1 |
| Marques, B | 1 |
| Monteiro, AR | 1 |
| Martins, RG | 1 |
| Couto, J | 1 |
| Rodrigues, F | 1 |
| Ribeiro, J | 1 |
| April-Monn, SL | 1 |
| Wiedmer, T | 1 |
| Skowronska, M | 1 |
| Maire, R | 1 |
| Schiavo Lena, M | 1 |
| Trippel, M | 1 |
| Di Domenico, A | 1 |
| Muffatti, F | 1 |
| Andreasi, V | 1 |
| Capurso, G | 1 |
| Doglioni, C | 1 |
| Kim-Fuchs, C | 1 |
| Gloor, B | 1 |
| Zatelli, MC | 1 |
| Partelli, S | 1 |
| Falconi, M | 1 |
| Perren, A | 2 |
| Marinoni, I | 1 |
| Spada, F | 2 |
| Maisonneuve, P | 2 |
| Fumagalli, C | 1 |
| Marconcini, R | 1 |
| Gelsomino, F | 2 |
| Antonuzzo, L | 1 |
| Campana, D | 2 |
| Puliafito, I | 1 |
| Rossi, G | 1 |
| Faviana, P | 1 |
| Messerini, L | 1 |
| Barberis, M | 1 |
| Fazio, N | 2 |
| Al-Toubah, T | 2 |
| Morse, B | 2 |
| Pelle, E | 2 |
| Strosberg, J | 2 |
| Cao, Y | 1 |
| Ma, Y | 1 |
| Yu, J | 1 |
| Sun, Y | 1 |
| Sun, T | 1 |
| Shao, Y | 1 |
| Li, J | 1 |
| Shen, L | 1 |
| Lu, M | 1 |
| Rogers, JE | 1 |
| Lam, M | 1 |
| Halperin, DM | 1 |
| Dagohoy, CG | 1 |
| Yao, JC | 1 |
| Dasari, A | 1 |
| Kobayashi, N | 1 |
| Takeda, Y | 1 |
| Okubo, N | 1 |
| Suzuki, A | 1 |
| Tokuhisa, M | 1 |
| Hiroshima, Y | 1 |
| Ichikawa, Y | 1 |
| Kesavan, M | 2 |
| Grover, P | 1 |
| Lam, WS | 1 |
| Claringbold, PG | 3 |
| Turner, JH | 3 |
| Lania, A | 1 |
| Ferraù, F | 1 |
| Rubino, M | 1 |
| Modica, R | 1 |
| Colao, A | 1 |
| Faggiano, A | 1 |
| Valone, T | 1 |
| Haider, M | 1 |
| Strosberg, JR | 2 |
| Gao, H | 1 |
| Dong, J | 1 |
| Zhang, W | 1 |
| Xu, H | 1 |
| Ye, L | 1 |
| Li, H | 1 |
| Ni, Q | 1 |
| Wang, W | 1 |
| Liu, L | 1 |
| Girot, P | 1 |
| Dumars, C | 1 |
| Mosnier, JF | 1 |
| Muzellec, L | 1 |
| Senellart, H | 1 |
| Foubert, F | 1 |
| Caroli-Bosc, FX | 1 |
| Cauchin, E | 1 |
| Regenet, N | 1 |
| Matysiak-Budnik, T | 1 |
| Touchefeu, Y | 1 |
| Klimstra, DS | 1 |
| Horvat, N | 1 |
| Zhang, L | 1 |
| Chou, JF | 1 |
| Capanu, M | 1 |
| Basturk, O | 1 |
| Do, RKG | 1 |
| Allen, PJ | 1 |
| Pellini Ferreira, B | 1 |
| Vasquez, J | 1 |
| Carilli, A | 1 |
| Walter, T | 4 |
| Pusceddu, S | 1 |
| Graillot, E | 1 |
| Prinzi, N | 1 |
| Spallanzani, A | 1 |
| Fiorentino, M | 1 |
| Barritault, M | 2 |
| Dall'Olio, F | 1 |
| Brighi, N | 1 |
| Biasco, G | 1 |
| Thakral, P | 1 |
| Sen, I | 1 |
| Pant, V | 1 |
| Gupta, SK | 1 |
| Dureja, S | 1 |
| Kumari, J | 1 |
| Kumar, S | 1 |
| Un, P | 1 |
| Malasani, V | 1 |
| Pozzari, M | 1 |
| Berruti, A | 1 |
| Amoroso, V | 1 |
| Cella, CA | 1 |
| Laffi, A | 1 |
| Pellicori, S | 1 |
| Bertani, E | 1 |
| Cheng, YJ | 1 |
| Meng, CT | 1 |
| Ying, HY | 1 |
| Zhou, JF | 1 |
| Yan, XY | 1 |
| Gao, X | 1 |
| Zhou, N | 1 |
| Bai, CM | 1 |
| de Mestier, L | 2 |
| Brixi, H | 1 |
| Evrard, C | 2 |
| Legoux, JL | 1 |
| de Boissieu, P | 2 |
| Hentic, O | 3 |
| Cros, J | 4 |
| Hammel, P | 3 |
| Tougeron, D | 2 |
| Lombard-Bohas, C | 3 |
| Rebours, V | 3 |
| Ruszniewski, P | 3 |
| Cadiot, G | 1 |
| Lemelin, A | 1 |
| Hervieu, V | 1 |
| Payen, L | 1 |
| Péron, J | 1 |
| Couvelard, A | 2 |
| Scoazec, JY | 1 |
| Bin, S | 1 |
| Villeneuve, L | 1 |
| Costa, FP | 1 |
| Gumz, B | 1 |
| Pasche, B | 1 |
| Chan, JA | 1 |
| Blaszkowsky, L | 1 |
| Stuart, K | 3 |
| Zhu, AX | 1 |
| Allen, J | 1 |
| Wadlow, R | 1 |
| Ryan, DP | 3 |
| Meyerhardt, J | 1 |
| Gonzalez, M | 1 |
| Regan, E | 1 |
| Zheng, H | 1 |
| Kulke, MH | 4 |
| Saif, MW | 2 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Rodriguez, T | 1 |
| Tejani, MA | 1 |
| Schmitt, AM | 1 |
| Pavel, M | 1 |
| Rudolph, T | 1 |
| Dawson, H | 1 |
| Blank, A | 1 |
| Komminoth, P | 1 |
| Vassella, E | 1 |
| Rashidi, A | 1 |
| Sorscher, SM | 1 |
| Okusaka, T | 1 |
| Ueno, H | 1 |
| Morizane, C | 1 |
| Kondo, S | 1 |
| Sakamoto, Y | 1 |
| Takahashi, H | 1 |
| Ohno, I | 1 |
| Shimizu, S | 1 |
| Mitsunaga, S | 1 |
| Ikeda, M | 1 |
| De Divitiis, C | 1 |
| von Arx, C | 1 |
| Grimaldi, AM | 1 |
| Cicala, D | 1 |
| Tatangelo, F | 1 |
| Arcella, A | 1 |
| Romano, GM | 1 |
| Simeone, E | 1 |
| Iaffaioli, RV | 1 |
| Ascierto, PA | 1 |
| Tafuto, S | 1 |
| Zappa, M | 1 |
| Gille, N | 1 |
| Theou-Anton, N | 1 |
| Vernerey, D | 1 |
| Maire, F | 1 |
| Lévy, P | 1 |
| Bedossa, P | 1 |
| Paradis, V | 1 |
| Cives, M | 1 |
| Ghayouri, M | 1 |
| Brelsford, M | 1 |
| Black, M | 1 |
| Rizzo, A | 1 |
| Meeker, A | 1 |
| Bracht, LK | 1 |
| Wen, P | 1 |
| Meyerhardt, JA | 2 |
| Hornick, JL | 2 |
| Redston, M | 1 |
| LaFrankie, DC | 1 |
| Black, PM | 1 |
| Kesari, S | 1 |
| Norden, A | 1 |
| Drappatz, J | 1 |
| Frauenhoffer, C | 1 |
| Hooshmand, S | 1 |
| Enzinger, PC | 2 |
| Clark, JW | 2 |
| Fuchs, CS | 2 |
| Redston, MS | 1 |
| Fine, RL | 1 |
| Choi, J | 1 |
| Nasir, A | 1 |
| Coppola, D | 1 |
| Chen, DT | 1 |
| Helm, J | 1 |
| Kvols, L | 1 |
| Gupta, S | 1 |
| Sathishkumar, S | 1 |
| Ahmed, MM | 2 |
| Thornton, R | 1 |
| Philippon, M | 1 |
| Morange, I | 1 |
| Barrie, M | 1 |
| Barlier, A | 1 |
| Taieb, D | 1 |
| Dufour, H | 1 |
| Conte-Devolx, B | 1 |
| Brue, T | 1 |
| Castinetti, F | 1 |
| Raymond, E | 1 |
| Dreyer, C | 1 |
| Faivre, S | 1 |
| Mayes, PA | 1 |
| Degenhardt, YY | 1 |
| Wood, A | 1 |
| Toporovskya, Y | 1 |
| Diskin, SJ | 1 |
| Haglund, E | 1 |
| Moy, C | 1 |
| Wooster, R | 1 |
| Maris, JM | 1 |
| Olsen, IH | 1 |
| Sørensen, JB | 1 |
| Federspiel, B | 1 |
| Kjaer, A | 1 |
| Hansen, CP | 1 |
| Knigge, U | 1 |
| Langer, SW | 1 |
| Ito, T | 1 |
| Igarashi, H | 1 |
| Jensen, RT | 1 |
| Takayanagi, R | 1 |
| Gronau, M | 1 |
| Jäger, D | 1 |
| Enk, AH | 1 |
| Hassel, JC | 1 |
| Kokkinakis, DM | 2 |
| Chendil, D | 1 |
| Moschel, RC | 1 |
| Pegg, AE | 1 |
| Liu, X | 1 |
| Neuner, RD | 1 |
| Muzikansky, A | 1 |
| Vincitore, M | 1 |
| Michelini, A | 1 |
| Moore, MJ | 1 |
| Feld, R | 1 |
| Hedley, D | 1 |
| Oza, A | 1 |
| Siu, LL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents[NCT03217097] | 116 participants (Actual) | Interventional | 2018-10-16 | Completed | |||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors[NCT03079440] | Phase 2 | 31 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for temozolomide and Cancer of Pancreas
| Article | Year |
|---|---|
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neo | 2021 |
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytoreduction Surgical Procedures; Hum | 2018 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell | 2012 |
Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine | 2015 |
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbaz | 2012 |
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immuno | 2012 |
9 trials available for temozolomide and Cancer of Pancreas
| Article | Year |
|---|---|
Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carc | 2021 |
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; | 2021 |
Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; D | 2018 |
O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; DNA Methylation; | 2019 |
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dru | 2013 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Da | 2016 |
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An | 2006 |
A phase II study of temozolomide in advanced untreated pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Middle Aged; Pancreati | 1998 |
38 other studies available for temozolomide and Cancer of Pancreas
| Article | Year |
|---|---|
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2015 |
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumo | 2022 |
Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Topics: Adult; Aged; Capecitabine; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mutation; Neuroendoc | 2023 |
Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Middle Aged; Neoa | 2020 |
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Female; Hepate | 2020 |
Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Insulin; Middle Aged; | 2020 |
Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cryopreservation; Drug Screening Assays, Antitumor; Everoli | 2021 |
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Italy; Neuroendocrine Tumors; | 2021 |
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Leucovorin; Neur | 2021 |
Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Female; Gallium Radioisotopes; Humans; Immunothera | 2020 |
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxo | 2022 |
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Neuroendocrine T | 2021 |
Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Humans | 2022 |
Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; | 2017 |
Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Biopsy; Capecitabine; Car | 2017 |
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Fe | 2018 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabin | 2018 |
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Humans; Male; M | 2020 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Ther | 2014 |
Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Daca | 2014 |
Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2015 |
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
Topics: Administration, Metronomic; Animals; Carcinoma, Neuroendocrine; Cell Differentiation; Dacarbazine; F | 2016 |
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2016 |
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2016 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2008 |
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Topics: Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Disease-Free Survival; Female; Huma | 2009 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Mismatch Repa | 2010 |
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine | 2012 |
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Di | 2012 |
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocy | 2013 |
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; D | 2012 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neur | 2013 |
Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Topics: Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarba | 2003 |
Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Blotting, Wester | 2005 |